the phytosterols, which are derived from the intestinal absorption of vegetable oils, margarines, spreads, grains, and certain fruits and vegetables. 5, 6 Although structurally similar to cholesterol, phytosterols (which include beta-sitosterol, campesterol, and stigmasterol) could affect levels of endogenous hormones through alterations in bile acid metabolism and estrogen reabsorption or by acting as substrates for synthesis of steroid hormones. 7 Previously, we have documented that self-reported use of hormone therapy was a significant protective factor for lung cancer in women. 8 We wished to further explore the compelling concept that estrogen or estrogen-like compounds play a role in chemoprevention. Specific chemopreventive effects putatively associated with phytoestrogens include cell cycle regulation, inhibition of invasion and metastasis, antioxidant activity, induction of apoptosis, inhibition of endothelial cell proliferation, and inhibition of angiogenesis. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In further support for a chemopreventive role of phytoestrogens, epidemiologic studies have revealed a relatively consistent association between higher intake of phytoestrogens and reduced risk for cancers of the breast, 21, 22 endometrium, 23, 24 and prostate. [25] [26] [27] In spite of the lungspecific in vitro and in vivo studies [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] that support a chemopreventive role for phytoestrogens, at present there is limited epidemiologic evidence for a role of phytoestrogens in risk of lung cancer, but, overall, results have been suggestive of a protective effect. [28] [29] [30] [31] [32] [33] To shed more light on the role of phytoestrogens in risk of lung cancer, we analyzed dietary intake and risk factor data from a case-control study designed to study genetic susceptibility to lung cancer. To our knowledge, this is the largest case-control study to examine dietary phytoestrogens and risk of lung cancer in a US population.
METHODS

Study Population
From July 1995 through October 2003, 1674 patients with lung cancer (cases) and 1735 matched healthy controls were accrued from an ongoing and previously described case-control study of lung cancer. 34 Case patients with histologically confirmed lung cancer were recruited prior to initiation of radiotherapy or chemotherapy from The University of Texas M. D. Anderson Cancer Center, Houston. There were no age, sex, ethnic, or stage restrictions. Healthy controls, without a previous diagnosis of cancer, were recruited from the Kelsey-Seybold Clinics, Houston's largest private multispecialty physician group, which includes a network of 23 clinics and more than 300 physicians. Controls were frequency matched to the cases on age (±5 years), sex, ethnicity, and smoking status (current, former, never). All cases and controls were US residents. To date, the response rate among both cases and controls has been approximately 75%. This research was approved by the M. D. Anderson Cancer Center and KelseySeybold institutional review boards, and all participants provided written informed consent.
Epidemiologic and Phytoestrogen Data
All study participants completed a personal interview to obtain information on demographics, socioeconomics (ie, annual income and education), and smoking history. Women were asked whether they had taken hormone therapy in the previous 6 months, and, if known, the type of hormone therapy was recorded. Ever smokers were defined as individuals who had smoked at least 100 cigarettes in their lifetime; of those, former smokers were defined as ever smokers who had quit smoking at least 1 year before diagnosis (cases) or before interview (controls). Race/ethnicity information (white, Hispanic, African American, or other) was obtained for matching purposes and to control for confounding and was self-reported by participants either as open-ended responses or by choosing race-ethnicity from an investigator-provided list.
Additionally, a food frequency questionnaire (a modified version of the National Cancer Institute's Health Habits and History Questionnaire 35 ) was used to collect dietary data. The questionnaire includes a semiquantitative food frequency list made up of food and beverage items, ethnic foods commonly consumed in the Houston area, an openended section, and other dietary behavior questions regarding such factors as dining at restaurants and food preparation methods. The questionnaire has been shown to be a valid and reliable food frequency tool across various populations. 36, 37 Study participants were asked about their diet during the year prior to diagnosis (cases) and the year prior to enrollment into the study (controls).
Nutrient intake was calculated using the DIETSYSϩPlus version 5.9 dietary analysis program (Block Dietary Data Systems, Berkeley, Calif). The DIETSYSϩPlus database has been expanded to include phytoestrogen values in edible parts of plant foods consumed in the United States. Detailed methods of the creation of the database, its limitations, 38 and its application to assess risk of prostate 25 and testicular 39 cancer have been published previously. To update the database, a detailed literature search was conducted for food values published after a study by Pillow et al, 38 and updated values were calculated and assigned to each food using published guidelines. 38 New food values were derived from published literature [40] [41] [42] [43] [44] and from a database maintained by the US Department of Agriculture, Agricultural Research Service. 45 Additionally, the DIETSYSϩPlus database was updated using release 16-1 of the US Department of Agriculture National Nutrient Database for Standard Reference. 46 For multi-ingredient dishes not available in release 16-1 or the updated phytoestrogen database, nutrient values were estimated as needed from appropriate recipes found in the Continuing Survey of Food Intakes by Individuals, 1994 Individuals, -1996 Individuals, , 1998 . 47 Recipe adjustments were made, where required, for moisture changes and nutrient loss due to cooking.
Summary measures of total phytoestrogen intakes were generated for phytosterols (summation of betasitosterol, campesterol, and stigmasterol), isoflavones (biochanin A, daidzein, genistein, and formononetin), lignans (enterolactone, enterodiol, matairesinol, and secoisolariciresinol), soy-derived isoflavones (daidzein and genistein), lignan precursors (enterolactone and enterodiol), and lignan metabolites (matairesinol and secoisolariciresinol). Summary measures of total phytoestrogen intake were generated based on the summation of each individual phytoestrogen and of those derived from food sources only, excluding phytoestrogens abundantly derived from coffee and tea, ie, betasitosterol, formononetin, matairesinol, and secoisolariciresinol.
Statistical Analysis
All analyses were performed using Intercooled STATA version 8.0 (Stata Corp, College Station, Tex). The Pearson 2 test was used to test the differences between the cases and controls in terms of sex, ethnicity, smoking status, education, and income. The t test was used to test differences in mean age, cigarettes smoked per day, years of smoking, and total intakes of energy, protein, fat, and carbohydrates. The Wilcoxon rank-sum test was used to test for differences in phytoestrogen intake. The Spearman rank correlation coefficient was used to test the correlation between each individual phytoestrogen. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated as an estimate of the relative risk. With 95% power and a 2-sided significance level of 5%, the study had statistical power to detect a significant OR of 0.76 (ie, a 24% reduced risk) for individuals in the highest quartile of intake.
Unconditional multivariable logistic regression analyses were performed to control for confounding by age, sex, ethnicity, smoking status, cigarettes smoked per day, years of smoking, education, income, body mass index (calculated as weight in kilograms divided by the square of height in meters), and total energy, where appropriate. The final logistic regression model includes variables that were considered biologically relevant and statistically significant in the multivariable model. Statistically significant variables were added if they improved the fit and predictive power of the model and if they were statistically significant by the likelihood ratio test. Matching variables were retained in the model to account for the possibility of residual confounding. Phytoestrogen intake was categorized by the quartile intake values in the controls. Trend tests for the quartiles of intake were performed by creating a categorical variable and assigning the score j to the jth quartile of intake. The categorical variable was treated as an interval predictor in the multivariable logistic models. In the joint-effects analyses, intake was dichotomized at the 75th percentile in the controls; intake above this cutpoint was considered "high." Interaction was tested on the multiplicative scale by entering product terms in the main-effects multivariable models.
RESULTS
Data from 1674 patients with lung cancer and 1735 controls were available for this analysis (TABLE 1) . There were no statistically significant differences between the cases and the controls in terms of age, sex, ethnicity, and smoking status. In general, cases reported heavier smoking histories. For current smokers, cases had smoked cigarettes for a mean of 40.1 (SD, 11.0) years compared with 38.5 (SD, 11.2) years for controls (P = .008), while among former smokers, mean duration of smoking was 32.6 (SD, 12.7) years for cases compared with 27.8 (SD, 12.1) years for controls (PϽ.001). There was no difference between cases and controls in number of cigarettes smoked per day for former smokers. However, cases were self-reported heavier current smokers (mean, 27. Although controls reported higher intakes of total protein, there were essentially no casecontrol differences in total intakes of energy, fat, and carbohydrates.
Overall, consumption of phytoestrogens was statistically significantly higher in controls than in cases (TABLE 2), attributed largely to variation in intake for men. In women, only intake of total phytoestrogens from food sources was statistically significantly higher in controls than in cases. Data on the isoflavone glycitein were excluded, since only 12% of the cases and 15% of the controls reported any intake. For the isoflavones daidzein and genistein, more than 86% of the cases and 96% of the controls reported some intake. All cases and controls reported some quantifiable intake for the other phytoestrogens. The phytoestrogen intakes were not energy adjusted, since there was no difference in total energy intake between cases and controls, total energy was not correlated with any of the phytoestrogens, and there were no appreciable differences in the results when energy-adjusted values were explored.
We also evaluated the top 5 food sources for each phytoestrogen (TABLE 3) and assessed the correlations between each individual phytoestrogen. The correlation coefficients were generally low for most of the phytoestrogens (ρ = −0.02 to 0.39), although some were moderately to highly correlated (ρ=0.49 to 0.99). The major dietary sources for beta-sitosterol, matairesinol, secoisolariciresinol, and formononetin were coffee and tea, and they were all moderately to highly correlated with each other (ρ=0.50 to 0.89). The lignan precursors matairesinol and secoisolariciresinol exhibited moderate correlation (ρ=0.55, PϽ.001). Additionally, the lignan metabolites enterolactone and enterodiol were highly correlated (ρ=0.89, PϽ.001), and both Overall, the reduction in risk of lung cancer was 24% (OR, 0.76; 95% CI, 0.61-0.94) for those with the highest intake of total phytoestrogens from all sources and 46% (OR, 0.54; 95% CI, 0.42-0.70) for highest intake of total phytoestrogens from food sources only. Both total phytoestrogen summary variables yielded statistically significant trends for decreasing risk with increasing intake. The highest quartile of each total phytoestrogen summary measure was also associated with reductions in risk of lung cancer ranging from 27% to 43% for men and 22% to 34% for women ( 6) . For current smokers, the highest quartiles of intake for each of the phytoestrogen groups were associated with significant reductions in risk ranging from 31% to 58%, and statistically significant trends were noted for all phytoestrogen groups except total phytoestrogens from food sources only (P=.16). For former smokers, the protective effects were generally attenuated, and statistically significant trends were observed only for total phytoestrogens from food sources and for soyderived isoflavones. Protective effects were evident for never smokers in all analyses, although the only statistically significant trends were observed for total intake of phytoestrogens from food sources.
As we demonstrated previously, 8 use of hormone therapy was significantly protective in the present analysis (OR, 0.74; 95% CI, 0.59-0.91). The combination of use of hormone therapy and high intake of enterolactone and enterodiol (TABLE 7) was associated with a 50% reduced risk (OR, 0.50; 95% CI, 0.31-0.68; P=.04 for interaction), compared with the 26% reduced risk for hormone therapy use alone and the 27% reduced risk for high intake of enterolactone and enterodiol (OR, 0.73; 95% CI, 0.56-0.95). A similar trend but with lesser effects was observed for the joint effects of hormone therapy use and high intake of daidzein and genistein (OR, 0.58; 95% CI, 0.40-0.85; P=.79 for interaction) compared with the main effects of high intake (OR, 0.87; 95% CI, 0.67-1.11). There was no evidence for joint effects of hormone therapy use and total intake of phytoestrogens from food sources, and there was no evidence of statistical interaction (P=.13 for interaction).
COMMENT
Because we have previously shown that use of hormone therapy was a statistically significant protective factor for lung cancer in women, 8 in this article we used a food frequency questionnaire to assess phytoestrogen intake to determine whether dietary phytoestrogens also modulate risk of lung cancer. Our main findings were that patients with lung cancer tended to consume lower amounts of phytoestrogens than controls, that there were sex-specific differences both in intake and in protective effects, and that the apparent benefits were evident in both never and current smokers but less so in former smokers. The present study, with a sample size of 1674 cases and 1735 controls, had reasonable power to detect small to moderate statistically significant ORs. As expected, there was a dose-response relationship evident, with reduction in risk with each increasing quartile of phytoestrogen intake. The highest quartiles of total phytosterols, isoflavones, lignans, and phytoestrogens were each associated with protective effects ranging from 21% to 46%. Sex-specific analyses were performed since there are sex-dependent differences in the presence of estrogen receptors in lungs. 48 For men, statistically significant trends were noted for each phytoestrogen, while in women, significant trends were only present for phytoestrogens from all sources. Although estrogen receptors have been detected to a greater extent in adenocarcinomas than in squamous cell cancers, 49 no appreciable differences in the ORs were observed when the data were explored for histology-specific effects.
In addition to a variety of chemopreventive effects, 9-20 phytoestrogens possess both estrogen agonist and antagonist properties, which in turn may be responsible for some of their putative benefits, such as cardioprotection, reduced osteoporosis, increased cognitive function, and chemoprevention. Many phytoestrogens have a particular affinity for estrogen receptors that are present in normal and malignant lung tissue 50 and could have a role in the regulation 51 or deregulation of cancer growth and hormonal responsiveness.
Most of the epidemiologic evidence supporting a role for phytoestrogens in risk of lung cancer has come from studies in Asian populations, [28] [29] [30] [31] [32] who typically consume large quantities of phytoestrogens. Wakai et al 28 observed that nonfermented soy foods protected against lung cancer in Japanese men, and a reduced risk of squamous cell carcinoma was observed for consumption of tofu, a rich source of phytoestrogens, in both men and women. Reduced risk for lung cancer with soy consumption has also been reported in several studies in China. [29] [30] [31] [32] In a prospective study in Finland, dietary flavonoids, a broad group of compounds that include isoflavones, were also inversely associated with risk of lung cancer. 33 Although several of the phytoestrogens in this study were derived from coffee and tea, at present there is inconsistent epidemiologic evidence to support a relationship between coffee or tea consumption and risk of lung cancer. In fact, both have been reported to be protective, 52 to have no effect, 53, 54 and to be a putative risk factor for lung cancer. 53, 55, 56 Thus, to explore the effects of phytoestrogens from food sources only, we excluded the specific phytoestrogens abundantly derived from coffee and tea. The highest quartile of phytoestrogens from food sources was associated with an overall 46% reduction in risk, with substantial protective effects for both men and women, and with statistically significant trends for decreasing risk with in- Abbreviations: CI, confidence interval; OR, odds ratio. *Adjusted for age, sex, ethnicity, smoking status, cigarettes smoked per day, years of smoking, education, income, body mass index, and total energy, where appropriate. †Excluding phytoestrogens from coffee and tea sources, ie, beta-sitosterol, formononetin, matairesinol, secoisolariciresinol.
creasing intake. On the other hand, when the lignan precursors were combined, there was a 27% reduction in risk of lung cancer for the highest quartile of consumption, with a statistically significant trend overall and for men.
For total isoflavones, there were substantial protective effects with increasing quartiles overall and for men, but statistically significant protective effects were not found for women. The median intake of total isoflavones for women controls was 588.9 µg/d (approximately 0.6 mg/d). By comparison, Seow et al 32 reported an intertertile range of 9.9 to 24.5 mg/d of total isoflavones for healthy Singapore Chinese women, and Horn-Ross et al 23 reported a median intake of 1.7 mg/d among healthy women in the San Francisco Bay Area. Duncan et al 21 estimated isoflavone intakes to be about 25 to 40 mg/d for Asian women and less than 1 mg/d for postmenopausal women living in the United States. Although isoflavone estimates in the present study may be lower compared with those in other studies, they are not necessarily underestimated. Since soy foods are major contributors to isoflavone intake, diets of Asian origin or in areas with a considerable Asian population, such as San Francisco, typically would have much higher soy isoflavone content. Therefore, regional differences could contribute to the differences in the reported values. We could not compare values for men, since at present there are no published data available.
We analyzed the isoflavones genistein and daidzein together, since they were highly correlated; are abundantly derived from soy food sources; and because soy has been identified as having an important role in reducing the risk of various epithelial cancers, including lung cancer. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [28] [29] [30] [31] [32] [33] Statistically significant trend tests were found for the protective effects of increasing soy intake, and there was an overall 61% protective effect (72% reduction for men and 44% for women) in the highest quartile of soy isoflavone intake.
The highest quartile of total lignans was also associated with an overall significant protective effect for men but not for women. Because lignan metabolites are not found in plant foods and are actually derived from lignan precursors, we opted to sum the lignans and to separate the precursors from the 57 folate, 58 and carotenoids. 59 Phytosterols are not classified as a phytoestrogen, but they are a weak agonist for estrogen receptors, 60 a potential environmental endocrine disruptor, 61 and have chemopreventive properties including anti-inflammatory, antipyretic, 62 antineoplastic, and immune modulation. 63 In this study, phytosterols were generally correlated with the lignans, derived from food sources similar to those of the other phytoestrogens, and were associated with statistically significant trend tests overall and for men. High dietary intake of phytosterols has been associated with decreased risks for cancers of the lung, 64 prostate, 25 ovary, 65 stomach, 66 and endometrium. 67 In this study, generally, the highest quartiles of intake were associated with significantly protective effects in current smokers and even greater protective effects in never smokers, although many of the estimates did not achieve statistical significance because of the small number of never smokers in this study. Furthermore, the protective effects were generally attenuated in former smokers. Overall, these data suggest that phytoestrogens are significantly protective for lung cancer in current smokers. However, the effects observed for never smokers are important because never smokers have a relatively low risk of lung cancer, and benefits from chemopreventive agents would be expected to be modest. We have previously shown that use of hormone therapy was associated with a statistically significantly reduced risk of lung cancer in current smokers but not in never or former smokers. 8 We explored the joint effects of phytoestrogen intake and use of hormone therapy because we, and others, 8, [68] [69] [70] have previously provided epidemiologic evidence that use of hormone therapy is associated with a decrease in lung cancer risk, and since there has been no study exploring such effects. For these analyses, we specifically explored the lignan metabolites, soy isoflavones, and total phytoestrogens from food sources because they yielded significant main effects and trends for women. The protective effects for high phytoestrogen intake and use of hormone therapy together were greater than the protective effects of high intake alone and use of hormone therapy alone. Additionally, the interaction term between use of hormone therapy and the lignan metabolites was statistically significant. These findings certainly cannot be considered causal, but they do suggest that the protective effects of hormone therapy use and phytoestrogen intake may be independent factors that act together to further reduce risk of lung cancer in women. Although the biological mechanism(s) of hormone therapy on lung cancer is not yet known, estrogen and other steroid receptors are present in both malignant and nonmalignant lung tissue. 48, 50, 51 Therefore, it is likely that endogenous estrogen and estrogenlike compounds have lung-specific effects.
Although this article provides the first quantitative assessment of the association between phytoestrogens and risk of lung cancer in a US population, there are inherent limitations in such nutritional epidemiology analyses. Selection bias, recall bias, and confounding are major concerns in case-control studies of diet and cancer. 71 Although food frequency questionnaires are subject to inherent limitations such as random and systematic error, 72, 73 we attempted to minimize recall bias and improve accuracy of reporting through use of personal interviews, as opposed to self-administered forms, and included an assessment of portion size using visual aids.
Additionally, our updated database developed for use with our food fre- Abbreviations: CI, confidence interval; OR, odds ratio. *Phytoestrogen intake dichotomized at the 75th percentile in the controls. Intake Ն75th percentile is categorized as "high" and Ͻ75th percentile as "low." †Data on use of hormone therapy were missing for 7 cases and 5 controls. ‡Adjusted for age, ethnicity, smoking status, cigarettes smoked per day, years of smoking, education, income, body mass index, and total energy. §Excluding phytoestrogens from coffee and tea sources, ie, beta-sitosterol, formononetin, matairesinol, secoisolariciresinol.
